Inhibitor for narcotic analgesic dependence/resistance acquisition
March 19, 2018. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesPhenylacetamide derivative analgesics Pyrrolidinylalkylcarboxylic acid amide derivatives, their preparation and pharmaceutical compositions containing them Guanfacine in treating opiate addiction Method for treatment of substance addiction Cholecystokinin antagonists Process for preparing pyrrolidinylacetamide derivatives Method for treatment of substance addiction Patent #: 5468749 InventorsAssigneeApplicationNo. 000236 filed on 03/19/1998US Classes:514/424, Chalcogen bonded directly to the five-membered hetero ring by nonionic bonding514/343The additional hetero ring consists of one nitrogen and four carbons (e.g., nicotine, etc.)ExaminersPrimary: Jarvis, William R. A.Attorney, Agent or FirmForeign Patent References
International ClassesA61K 031/40A61K 031/44 Foreign Application Priority Data1995-08-07 JPAbstractA medicament which comprises as an active ingredient a compound represented by the following formula: R2 -CH2 CONH-R1 wherein R1 represents a pyridyl group, a substituted pyridyl group, phenyl group, or a substituted phenyl group; and R2 represents 2-oxo-1-pyrrolidinyl group which may optionally be substituted, and inhibits the development of dependency induced by a narcotic analgesic and/or inhibit the development of tolerance to analgesic action induced by a narcotic analgesic agent.Other References
| |
